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Background & Aims: Of the 2 genes (MAT1A, MAT2A)
encoding methionine adenosyltransferase, the enzyme
that synthesizes S-adenosylmethionine, MAT1A, is ex-
pressed in liver, whereas MAT2A is expressed in extra-
hepatic tissues. In liver, MAT2A expression associates
with growth, dedifferentiation, and cancer. Here, we
identified the  subunit as a regulator of proliferation in
human hepatoma cell lines. The  subunit has been
cloned and shown to lower the Km of methionine adeno-
syltransferase II 2 (the MAT2A product) for methionine
and to render the enzyme more susceptible to S-adeno-
sylmethionine inhibition.Methods:Methionine adenosyl-
transferase II 2 and  subunit expression was analyzed
in human and rat liver and hepatoma cell lines and their
interaction studied in HuH7 cells.  Subunit expression
was up- and down-regulated in human hepatoma cell
lines and the effect on DNA synthesis determined.
Results: We found that  subunit is expressed in rat
extrahepatic tissues but not in normal liver. In human
liver,  subunit expression associates with cirrhosis and
hepatoma.  Subunit is expressed in most (HepG2, PLC,
and Hep3B) but not all (HuH7) hepatoma cell lines.
Transfection of  subunit reduced S-adenosylmethi-
onine content and stimulated DNA synthesis in HuH7
cells, whereas down-regulation of  subunit expression
diminished DNA synthesis in HepG2. The interaction
between methionine adenosyltransferase II 2 and 
subunit was demonstrated in HuH7 cells. Conclusions:
Our findings indicate that  subunit associates with
cirrhosis and cancer providing a proliferative advantage
in hepatoma cells through its interaction with methio-
nine adenosyltransferase II 2 and down-regulation of
S-adenosylmethionine levels.
Methionine adenosyltransferase enzymes (MAT I,MAT II, and MAT III) have recently been impli-
cated as playing a role in cirrhosis and cancer.1–3 In
mammals, 2 different genes, MAT1A and MAT2A, en-
code for 2 homologous MAT catalytic subunits, 1 and
2.4–6 MAT1A is expressed mostly in the liver, and it
encodes the 1 subunit found in 2 native MAT isoen-
zymes, which are either a dimer (MAT III) or tetramer
(MAT I) of this single subunit.6 MAT2A encodes for a
catalytic subunit (2) found in a native MAT isoenzyme
(MAT II), which is widely distributed.4,6 MAT2A and
its gene product also predominate in the fetal liver and
are progressively replaced by MAT1A during develop-
ment.7,8 MAT1A gene is specifically silenced by hyper-
methylation in human cirrhosis,9 which leads to a
marked reduction of S-adenosylmethionine synthe-
sis.10,11 In adult liver, increased expression of MAT2A is
associated with rapid growth or dedifferentiation of the
liver. Thus, a switch in the gene expression from
MAT1A to MAT2A has been found in liver cancer,9,12,13
from 12 to 24 hours after partial hepatectomy in the
rat,14 and after treatment with thioacetamide.15 Using a
cell line model that differs only in the type of MAT
expressed, it has been demonstrated that the type of
MAT expressed by the cell significantly influences the
rate of cell growth.16 The mechanism is likely via a
change in the steady state S-adenosylmethinone content.
This is because MAT isoenzymes differ in kinetic param-
eters and regulatory properties,2 so a switch in MAT
expression can affect the steady state S-adenosylmethi-
onine content. MAT II has the lowest Km for methionine
but is tightly regulated by S-adenosylmethionine with
an IC50 of 60 mol/L, which is close to the normal
intracellular hepatic S-adenosylmethionine concentra-
tion.17–19 In contrast, S-adenosylmethionine has a mini-
mal inhibitory effect on MAT I and stimulates MAT
III.19 Thus, the S-adenosylmethionine content in cells
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that express only the MAT II isoform is relatively unaf-
fected by fluctuations in methionine availability because
of the negative feedback inhibition. In contrast, the rate
of S-adenosylmethionine synthesis and S-adenosylmethi-
onine level increased with increasing methionine avail-
ability in cells that express mostly MAT I/III.18–20 Con-
sistent with this, cells that express MAT1A have much
higher levels of S-adenosylmethionine but lower rates of
cell growth than cells that express MAT2A.16 A caveat to
this is the recently described regulatory  subunit that is
associated with MAT II in lymphocytes.21–23 The 
subunit was shown to lower the Km of MAT II for me-
thionine and render the enzyme more susceptible to feed-
back inhibition by S-adenosylmethionine.22 Whether the
 subunit regulates MAT II similarly in other cells is
unknown. The biologic function of  subunit is also
unknown.
Recently, we showed the importance of MAT1A in
maintaining a normal liver phenotype using the MAT1A
null mice.1 Three-month-old MATO mice express
MAT2A, have reduced hepatic S-adenosylmethionine
and GSH levels, hyperplasia, spontaneous oxidative
stress, increased cytochrome P4502E1 and uncoupling
protein 2 expression, are prone to fatty liver induced by
a choline-deficient diet, and are more susceptible to
carbon tetrachloride (CCl4)-induced liver injury.1,3 On a
normal diet, MATO mice develop non-alcoholic steato-
hepatitis by 8 months and hepatocellular carcinoma
(HCC) by 18 months,1,3 suggesting that MAT1A can
function as a tumor suppressor gene in the liver. Our
recent studies have also revealed that S-adenosylmethi-
onine plays a central role in regulating hepatocyte cell
growth, differentiation, and death. S-adenosylmethi-
onine blocks the mitogenic effect of hepatocyte growth
factor and inhibits cell-cycle progression.24 S-adenosyl-
methionine is antiapoptotic in normal hepatocytes but
proapoptotic in hepatoma cells.25 Taken together, these
data suggest that a normal hepatic S-adenosylmethionine
level favors the differentiated state of hepatocytes, blocks
apoptosis, and prevents cell proliferation. A fall in he-
patic S-adenosylmethionine level facilitates liver regen-
eration but, if this conditions persists, predisposes to
liver injury, steatohepatitis, and, finally, to the develop-
ment of HCC.
In this study, we evaluated the  subunit as a candi-
date regulator of growth in human hepatoma cell lines
through its interaction with MAT II and the down-
regulation of S-adenosylmethionine levels. We report
here that the  subunit gene was frequently expressed in
human cirrhotic livers and HCC and in some (HepG2,
PLC, and Hep3B) but not all (HuH7) human hepatoma
cell lines. In addition, transfection of the  subunit
reduced S-adenosylmethionine content and stimulated
DNA synthesis in HuH7 cells, whereas inhibition of 
subunit expression in HepG2 cells had the reversed
phenotype.
Materials and Methods
Cloning and Expression of MAT II 2 and
 Subunits
Total human resting peripheral blood lymphocyte
RNA was isolated by the guanidinium thiocyanate method26
and transcribed to cDNA using the Superscript preamplifica-
tion system (Invitrogen, Barcelona, Spain). The cDNA was
amplified using Taq Long Plus enzyme (Stratagene, La Joya,
CA) and the  sense 5-CAGCAAATGGGTATGGT-
GGGGCGGGAGAAAG-3 and antisense 5-CTAATGAAA-
GACCGTTTGTCTCCATC-3 primers, derived from the
human MAT II  subunit cDNA sequence.23 A T7 sense
5-GGATGGCTAGCATGACTGGTGGACAGCAAATGGG-3
primer was used to incorporate a T7 tag in the 5 of the MAT
II  subunit. The MAT II 2 subunit was cloned from the
same source using a 5-AGCATGGGCCACCATCACCAT-
CACCATATGAACGGACAGCTCAAC-3 sense primer,
which incorporated the His tag epitope, and an antisense
5-TCAATATTTAAGCTTTTTGGGCA-3 primer derived
from the human MAT II 2 subunit cDNA.4 The PCR
products were purified using QIAquick Gel Extraction kit
(Qiagen, Valencia, CA) and ligated into the expression vector
pCR3.1-Uni, according to the supplier’s instructions (Eukary-
otic TA cloning Kit Unidirectional, Invitrogen). The cloned
products were sequenced and their identities confirmed as the
full length MAT II 2 and  subunit coding sequences.
Cell Culture and Transfections
The human HepG2, PLC, HuH7, and Hep3B HCC-
derived cell lines were obtained from the American Type
Culture Collection (ATCC, Manassas, VA). Cells were man-
tained in Eagle’s minimum essential medium supplemented
with 5% fetal calf serum, 2 mmol/L glutamine, 100 U/mL
penicilin, and 100 g/mL streptomycin (all from Life Tech-
nologies/Invitrogen) at 37°C in a humid atmosphere of 5%
CO2 in air.
Plasmids PCR3.1 MAT II2 and PCR3.1 MAT II ,
containing the MAT II 2 and  subunits, respectively, or the
empty vector (PCR3.1 CAT) were independently prepared in
large quantities by using the Qiagen plasmid Kit (Qiagen)
according to the supplier’s instructions. Twelve g of each
plasmid were used to transfect HuH7 cells grown at 70%
confluency in 60-mm tissue culture plates using a Lipo-
fectamin Reagent Transfection System (Life Technologies/In-
vitrogen). Transfection efficiency was always around 50%, as
determined by immunofluorescent staining of transfected
HuH7 cells (see below).
HepG2 cells were seeded at a density of 104 cells/well
in 96-well plates in Dulbecco’s modified Eagle’s medium
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(DMEM) supplemented with 10% fetal calf serum and grown
for 24 hours. Transfections were performed with the following
oligonucleotides: 5-ACCATGCCCGCCGTCTTCAC-3 (an-
tisense to  subunit mRNA), and a second oligonucleotide
containing the same bases but in a random order (“scrambled”
oligonucleotide) was used for control experiments (5-GCTC-
CATCCGACCTGATCC-3). These oligonucleotides were
synthesized by Sigma-Genosys, and the first 2, 5 and 3
internucleotide linkages were modified as phosphorothioates.
The transfection mixture contained 200 nmol/L (final concen-
tration) of the above described oligonucleotides and 0.8 L of
Oligofectamine (Invitrogen) in Opti-MEM I medium (Invitro-
gen) (100 L final volume). After 4 hours incubation in this
mixture, 50 L of DMEM supplemented with 15% fetal calf
serum were added per well, and incubations were continued for
another 24 hours before DNA synthesis was measured as
described below.
RNA Isolation and Northern Hybridization
Analysis
Total RNA was isolated by the guanidinium thyoci-
anate method as described.9,26 RNA concentration was deter-
mined spectrophotometrically before use, and the integrity was
checked by electrophoresis with subsequent ethidium bromide
staining. Electrophoresis of RNA and gel blotting were carried
out as described.24 Northern hybridization analysis was per-
formed on total RNA using standard procedures as described
by Avila et al.27 All probes were labeled with [32P]dCTP using
a random primer kit (RediPrime DNA Labeling System, Am-
ersham Bisociences, Uppsala, Sweden). To ensure equal load-
ing of RNA samples, membranes were also hybridized with
32P-labeled 18S rRNA cDNA probe.
Immunoblot Analysis
Transfected cells were scraped and lysed by sonication
in phosphate-buffered saline solution containing 1% of pro-
tease inhibitor cocktail (Sigma, St. Louis, MO). Equal amounts
of protein (20 g) were subjected to 12% sodium dodecylsul-
fate polyacrylamide gel electrophoresis (SDS-PAGE) and then
electrophoretically transferred to nitrocellulose membranes as
described.27 Blots were incubated with mouse anti-T7 tag
(Novagen, Madison, WI) or anti-His tag antibodies (Invitro-
gen) diluted 1:500 for 1 hour. The blots were developed with
secondary anti-mouse antibodies conjugated to horseradish
peroxidase (Invitrogen) and the luminol-chemiluminescence
reagent (ECL, Amersham Biosciences). The processed blots
were exposed to x-ray film, and the autoradiograms were
analyzed.
MAT II 2 and  Subunits Interaction
The association between the His-tagged 2 subunit
and the T7-tagged  subunit was analyzed by Protein A
immunoprecipitation (Seize X Protein A Immunoprecipitation
Kit; Pierce, Rockford, IL). HuH7 cells were transfected with
PCR3.1 MAT II 2, PCR3.1 MAT II , or both; controls were
transfected with PCR3.1 CAT. Twenty-four hours after trans-
fection, cells (5  106) were lysed in 500 microliters of lysis
buffer (M-PER Reagent, Pierce). The samples were centrifuged
at 13,000 rpm for 10 minutes, and the supernatants were
diluted 1:1 with binding buffer and loaded onto protein
A-agarose columns cross-linked with anti-His antibodies
(Seize X Protein A Immmunoprecipitation Kit, Pierce). The
columns were washed with quenching/wash buffer 4 times,
and the proteins were eluted with elution buffer, pH 2.8,
following manufacturer’s instructions. Proteins were analyzed
by SDS-PAGE as described above. After blotting onto nitro-
cellulose membranes, blots were probed with anti-His tag and
anti-T7 tag antibodies.
Isolation and Culture of Rat Hepatocytes
Liver cells were isolated from male Wistar rats (200–
250 g) by collagenase (Invitrogen) perfusion as described pre-
viously.27 Cells were plated onto 60-mm collagen-coated cul-
ture dishes (type I collagen from rat tail; Collaborative
Biomedical Products, Bedford, MA) at a density of 3  106
cells per dish. Cultures were maintained in minimal essential
medium (Invitrogen), supplemented with 10% fetal calf serum
(Invitrogen), essential amino acids (Invitrogen), 2 mmol/L
glutamine, 50 mmol/L penicillin, and 50 mg/mL streptomycin
sulfate (Invitrogen). After 2-hour incubation, the culture me-
dium was removed, and cultures were again given the same
medium with 2.5% fetal calf serum. Cell viability was mea-
sured by trypan blue exclusion, and no significant differences
were observed at any time between controls and any of the
different treatments performed in this study. Animals were
treated humanely, and this study was approved by our insti-
tution’s Committee for Animal Experimentation.
Assay of DNA Synthesis
For DNA synthesis experiments, HuH7 were plated at
a density of 5  104 cells/well in a 96-well plate and trans-
fected with PCR3.1 MAT II  or PCR3.1 CAT as described
above. Twenty-four hours posttransfection, the medium was
replaced by fresh minimal essential medium without fetal
bovine serum, containing increasing concentrations of L-me-
thionine. A 6-hour pulse of [3H]thymidine (25 Ci/mmol,
Amersham Biosciences) (1 Ci/well) started 6 hours after
L-methionine addition. Cells were harvested, and thymidine
incorporation was determined in a scintillation counter.
HepG2 cells were transfected with the antisense oligonucleo-
tide to  subunit mRNA and control oligonucleotide as
described above, and DNA synthesis was assayed following the
same protocol used for HuH7 cells.
Determination of S-Adenosylmethionine
and S-Adenosylethionine Content in
HuH7 Cells
For the determination of S-adenosylmethionine and
S-adenosylethionine (SAE) in HuH7, cultures were washed
with phosphate-buffered saline, and, subsequently cells (5 
106) were lysed and deproteinized as described.24 S-adenosyl-
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methionine and SAE contents were determined by reverse-
phase, high-performance liquid chromatography as de-
scribed.27
Cell Staining
The HuH7 cells were transfected with PCR3.1 MAT
II , and 24 hours after transfection, cells were fixed in
iced-methanol as described.28 The anti-T7 antibody was used
at 1:50 dilution, the secondary antibody (anti-mouse IgG
fluorescein-conjugated; Sigma) at 1:200 dilution.
Patients
We have studied a group of 25 patients (16 males and
9 females; mean age, 54 8.5 years) with cirrhosis of different
etiology (12 hepatitis C virus [HCV]-induced cirrhosis, 12
alcoholic cirrhosis, 1 hepatitis B virus [HBV]-induced cirrho-
sis). The control group for the cirrhotic patients consisted of 16
subjects in whom a cholecystectomy was performed for the
treatment of a symptomatic cholelithiasis and who consented
to a liver biopsy during the surgical procedure. Liver samples
were immediately frozen and kept at 80°C until processed.
In the control group, both the liver function tests and the liver
biopsy were normal. Cancerous liver tissues were obtained
from 16 liver patients undergoing surgical resection for pri-
mary HCC. The contamination of HCC samples with noncan-
cerous tissue was less than 5% as determined by histopathol-
ogy. These tissues were immediately frozen in liquid nitrogen
for subsequent isolation of RNA. Written informed consent
was obtained from each patient. This study was approved by
the Human Research Review Committee of the University of
Navarra, Hospital Clı´nic of Barcelona, and Hospital Prı´ncipe
de Asturias, Alcala´ de Henares (Spain).
RT-PCR Studies
Total RNA was extracted from liver biopsy specimens
as previously described.9 Aliquots of 2 g of RNA were
reverse transcribed using the M-MLV Reverse Transcriptase
(Invitrogen) and subsequently amplified by PCR using the
BioTaq DNA Polymerase (Bioline, London, United King-
dom). The primers used for the MAT II  subunit were
5-TGGAGGAGGAAGTTAACATCCC-3 and 5-GGCCA-
CATCTTTGACATGTGTG-3. To avoid amplification of
genomic DNA, which could contaminate our RNA prepara-
tions, these primers were designed flanking intronic sequences.
Eighteen S rRNA was simultaneously amplified using the
Alternate 18S Internal Standards primers set (Ambion, Austin,
TX) and served as an internal loading control. Reactions were
resolved in a 2% agarose gel, stained with ethidium bromide,
and quantitated using the Molecular Analyst software (Bio-
Rad, Hercules, CA).
Statistics
Data are the means  SEM of at least 3 independent
experiments. Statistical significance was estimated with Stu-
dent t test. A P value of  0.05 was considered significant.
Results
 Subunit Is Expressed in Extrahepatic
Tissues but Not in Normal Adult Liver
Because the  subunit has been purified in asso-
ciation with MAT II 2,21–23 we first determined the
expression of  subunit in several rat tissues that express
only MAT2A spleen, heart, and lung and in normal adult
rat liver, which expresses MAT1A and also small
amounts of MAT2A. As shown in Figure 1,  subunit
gene was expressed in all extrahepatic tissues examined,
but, in normal adult liver, its expression was very weak
or undetectable.
 Subunit Is Frequently Expressed in
Cirrhosis, in Hepatocellular Carcinoma,
in Hepatoma Cell Lines, and in Culture
Hepatocytes
We have previously demonstrated that MAT1A
promoter is methylated and silenced both in cirrhosis
and in HCC9,29 and that MAT2A expression is markedly
induced in HCC.9,16 We therefore examined the expres-
sion of  subunit in 16 normal and 25 cirrhotic human
livers and in 16 human HCC. According to the expres-
sion levels of  subunit, samples were distributed in 3
groups: group 1: undetectable levels, group 2: low levels,
and group 3: high levels of expression. Only 4 normal
livers (25%) showed small but significant expression of 
subunit. In cirrhosis, 21 of 25 liver samples (84%)
expressed  subunit (48% in group 2 and 36% in group
3). No correlation could be established between the
different etiologies of cirrhosis and the expression of 
subunit. All HCC samples expressed  subunit (Figure
2A ). As a rule, expression of  subunit was more intense
in HCC than in cirrhosis (Figure 2A ). Expression of 
Figure 1. Expression of  subunit, MAT2A and MAT1A in rat tissues
as analyzed by Northern blotting. Hybridization with an 18S rRNA
probe was carried out as loading control.
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subunit was also observed in diethylnitrosamine-induced
HCC in rats (not shown). Moreover, most (HepG2, PLC,
and H3B) but not all (HuH7) human hepatoma cell lines
examined expressed  subunit (Figure 2B). Because
MAT2A is induced in culture hepatocytes and MAT1A
mRNA levels decrease,30 a situation reminiscent of that
found in fetal and regenerating liver and in HCC, we also
examined  subunit expression in hepatocytes in culture.
As shown in Figure 3, MAT2A expression in culture
hepatocytes is accompanied by a marked increase in 
subunit expression. Thus, the  subunit is frequently
expressed in human cirrhosis, in HCC, in hepatoma cell
lines, and in culture hepatocytes.
Transfection of  Subunit Reduced
S-Adenosylmethionine Content and
Stimulated DNA Synthesis in HuH7 Cells
The high frequency of  subunit expression ob-
served in HCC and hepatoma cell lines suggested that
expression of  subunit might confer a selective advan-
tage. Because a variety of data indicate that S-adenosyl-
methionine inhibits the rate of growth of HCC31,32 and
hepatoma cell lines,16 and the  subunit has been shown
to render MAT II more susceptible to feedback inhibi-
tion by S-adenosylmethionine,22 we examined the effect
of  subunit transfection on S-adenosylmethionine con-
tent and DNA synthesis in HuH7 cells. Transient trans-
fection showed that HuH7 cells were well able to express
exogenous 2 and  subunits, as determined by Western
blot (Figure 4A and B). Immunofluorescent detection
showed that the expression of  subunit was cytosolic
(Figure 4C ). S-adenosylmethionine content increased less
with increasing methionine availability in HuH7 cells
that express  subunit than in control cells (Figure 5A ).
To exclude the possibility that reduced S-adenosylme-
thionine content in HuH 7 cells transfected with 
subunit was due to an increased utilization of S-adeno-
sylmethionine, cells were incubated with various concen-
trations of ethionine and the accumulation of SAE de-
termined. Ethionine is an analog of methionine that is
utilized by MAT to form SAE, a nonmetabolizable ana-
log of S-adenosylmethionine that accumulates into the
cells.20 SAE content increased less with increasing ethi-
onine availability in HuH7 cells that express  subunit
than in control cells (Figure 5B). Finally, transfection
with  subunit in HuH7 cells enhanced serum-induced
DNA synthesis in a methionine-dependent manner
(Figure 5C ). This effect was evident at 1000 mol/L
L-methionine, a concentration at which  subunit-
expressing HuH7 cells had significantly reduced S-ad-
enosylmethionine levels as compared with untransfected
controls. The significance of this effect (1.5-fold increase
with respect controls) is more meaningful when we con-
sider that the average transfection efficiency was about
50% of the cells.
Figure 2. (A) Expression of  subunit in the liver of control (C),
cirrhotic patients, and in hepatocarcinoma (HCC) samples. Subjects
were divided into 3 groups according to the levels of  subunit
expression: group 1, subjects with very low or nondetectable expres-
sion; group 2, subjects with a moderate expression; group 3, subjects
with high expression. The number of subjects per group is indicated
for each group analyzed. Representative RT-PCR reactions are shown.
18S ribosomal RNA was used as internal control. (B) Expression of 
subunit gene in human hepatocarcinoma cell lines as analyzed by
quantitative RT-PCR. 18S ribosomal RNA was used as internal control.
Figure 3.  Subunits MAT2A and MAT1A expression levels in cultured
rat hepatocytes. Rat hepatocytes were cultured as described in Ma-
terials and Methods.  subunits MAT2A and MAT1A mRNA levels were
evaluated by Northern blotting at the onset of cultures (time 	 0) and
after 12 and 24 hours of incubation. Representative blots are shown.
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The relevance of  subunit expression in the prolifer-
ation of human hepatoma cells was also demonstrated in
HepG2 cells. In this cell line, which as shown in Figure
2B expresses  subunit, we have inhibited the expression
of this gene using an antisense oligonucleotide (60%
reduction in  subunit mRNA levels; Figure 6A) and
measured serum-induced DNA synthesis under different
concentrations of L-methionine in the culture medium.
As shown in Figure 6B, the specific inhibition of 
subunit expression in HepG2 cells resulted in reduced
DNA synthesis when cells were incubated under increas-
ing concentrations of L-methionine. Taken together,
these findings indicate that  subunit expression indeed
provides a growth advantage to human hepatoma cells.
Figure 5. Effect of  subunit expression on S-adenosylmethionine
levels and SAE and serum-induced DNA synthesis in transiently
transfected HuH7 cells. (A ) HuH7 cells were transfected with
PCR3.1 CAT (controls, open bars) or PCR3.1 MAT II  (solid bars),
and S-adenosylmethionine levels were determined after 6 hours
incubation in the presence of different concentrations of L-methi-
onine. *P  0.05 with respect to control cells incubated with the
same concentration of L-methionine. (B) The same experiment as
above was performed, but L-methionine was substituted by L-
ethionine. *P  0.05 with respect to control cells incubated with
the same concentrations of L-ethionine. (C ) HuH7 cells were trans-
fected with either PCR3.1 CAT or PCR3.1 MAT II . Twenty-four
hours after transfection, cells were incubated for 6 hours in serum-
free medium with increasing concentrations of L-methionine; sub-
sequently, cultures were given a 6-hour pulse with [3H]thymidine
and then harvested, and thymidine incorporation was determined
in a scintillation counter. Values represent fold-change vs. their
respective controls (PCR3.1 CAT-transfected cells) for each L-
methionine concentration. *P  0.05 with respect to control
(PCR3.1 CAT) transfections. All experiments were performed at
least 3 times in duplicate.
Figure 4. Expression of MAT II 2 and  subunits after transient
transfection of HuH7 cells. (A) Western blot of total lysates from
HuH7 cells that were transfected with the PCR3.1 CAT vector (lane 1)
or with the PCR3.1 MAT II  vector harboring the  subunit cDNA with
a T7 tag (lane 2). (B) Western blot of total lysates from HuH7 cells that
were transfected with the PCR3.1 CAT vector (lane 1) or with the
PCR3.1 MAT II 2 vector harboring the MAT II 2 subunit cDNA with a
poly-His tag (lane 2). (C) Immunofluorescent detection of  subunit in
transiently transfected HuH7 cells. Twenty-four hours after transfec-
tion, cells were fixed with ice-cold methanol, permeabilized, and la-
beled with anti-T7 tag mouse monoclonal antibodies. Immune com-
plexes were detected by incubation with a fluorescein-conjugated
anti-mouse IgG (original magnification 400).
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 Subunit Interacts With the 2 Subunit of
MAT II in HuH7
To demonstrate that the 2 subunit of MAT II
and the  subunit interact, HuH7 cells were cotrans-
fected with MAT II 2 and  subunits. After transfec-
tion, cells were disrupted, and the cell extract passed
through a column containing a covalently cross-linked
antibody that recognized a poly-His epitope tag attached
to the 2 subunit in the expression vector. After wash-
ing, the proteins retained in the column were eluted and
the presence of the  subunit associated to the 2
subunit determined by Western analysis for the T7
epitope tag attached to the  subunit in the expression
vector (Figure 7). In agreement with previous findings in
COS cells,22,23 these results indicate that the 2 subunit
of MAT II and the  subunit interact in HuH7 cells.
Discussion
In this study, we have identified MAT II  sub-
unit as a protein that confers a growth advantage to
human hepatoma cells.  subunit was expressed in all rat
extrahepatic tissues examined, but, in normal adult rat
liver, its expression was very weak or undetectable. 
Subunit expression was detected in all primary HCC,
suggesting that  subunit expression is a common event
in liver cancer. Consistently,  subunit expression was
detected in 3 of 4 human hepatoma cell lines.  subunit
expression was also detected in most human cirrhosis
(84%) but only in 4 of 16 human normal adult livers
(25%), indicating that induced expression of hepatic 
subunit is often associated with human liver dysfunction.
Expression of  subunit was also induced in hepatocytes
in culture, suggesting that expression of this gene is
associated with liver dedifferentiation and growth. More-
over, transfection with  subunit enhanced serum-stim-
ulated DNA synthesis in HuH7 cells. The involvement
of  subunit in the control of DNA synthesis was further
demonstrated in the human hepatoma cell line HepG2,
in which the  subunit gene is expressed. In this cell
line, we observed that, when the expression of the 
subunit gene was down-regulated using an antisense
oligonucleotide, DNA synthesis was reduced at increas-
ing concentrations of L-methionine, as compared with
cells transfected with a control oligonucleotide.
Figure 6. Inhibition of  subunit gene expression in HepG2 cells
results in reduced DNA synthesis. (A) HepG2 cells were cultured in
96-well plates and transfected with 200 nmol/L of an antisense
oligonucleotide to  subunit mRNA or a control oligonucleotide as
described in the Materials and Methods section.  subunit mRNA
expression was examined 24 hours after the transfections by North-
ern blotting in nontransfected control cells (C), antisense-transfected
cells (AS), and cells transfected with a control “scrambled” oligonu-
cleotide (SC). Blots were probed with an 18S rRNA probe as loading
control. This is a representative blot of 3 independent experiments.
(B) HepG2 cells were transfected with an antisense oligonucleotide to
 subunit mRNA or a control “scrambled” oligonucleotide. Twenty-four
hours after transfection, cells were incubated for 6 hours in serum-
free medium with increasing concentrations of L-methionine; subse-
quently, cultures were given a 6-hour pulse with [3H]thymidine and
then harvested, and thymidine incorporation was determined in a
scintillation counter. Values represent fold-change vs. their respective
controls (“scrambled” oligonucleotide-transfected cells) for each L-
methionine concentration. *P  0.05 with respect to control (“scram-
bled” oligonucleotide) transfections. All experiments were performed
at least 3 times in duplicate.
Figure 7. MAT II 2 and  subunits interaction. Cellular protein
extracts were loaded onto a protein A agarose column cross-linked
with anti-His antibody. The proteins were eluted with elution buffer pH
2.8. Samples were analyzed by SDS-PAGE and transblotted onto
nitrocellulose membranes. Blots were probed with anti-His tag anti-
bodies (for MAT II 2) and anti-T7 tag antibodies (for MAT II). (Left
panel) Total cellular protein extracts from PCR3.1 CAT (lane 1), PCR
3.1 MAT II  (lane 2), PCR3.1 MAT II 2 (lane 3), and 2/ trans-
fected HuH7 cells (lane 4) simultaneously probed with anti-His and
anti-T7 tags antibodies. (Right panel) Proteins eluted from the protein
A agarose column cross-linked with anti-His tag antibodies from the
following: PCR 3.1CAT (lane 5), PCR 3.1 MAT II  (lane 6), PCR3.1
MAT II 2 (lane 7), and 2/ (lane 8) transfected HuH7 cells. Blot
was probed with anti-His and anti-T7 tags antibodies simultaneously.
This experiment was performed 3 times with equivalent results;
representative blots are shown. The higher amount of 2 in lanes 4
and 8 could represent an increased stability of the protein when
bound to .
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We have also demonstrated that the  subunit is a
cytosolic protein that interacts with the 2 subunit of MAT
II in HuH7 hepatoma cells. The  subunit has been shown
to lower the Km of purified MAT II 2 for methionine and
renders the enzyme more susceptible to feedback inhibition
by S-adenosylmethionine.22 Our results indicate that trans-
fection with  subunit reduced the cellular content of
S-adenosylmethionine in HuH7 cells, which agrees with
the negative feedback inhibition that the  subunit exerts
on MAT II 2 activity. This effect of  subunit expression
on S-adenosylmethionine levels in HuH7 cells was accom-
panied by increased DNA synthesis when cells were in-
duced to proliferate by serum treatment. There is abundant
evidence indicating that S-adenosylmethionine has a
growth modulatory effect in liver, HCC, and hepatoma cell
lines. This has been observed in rat liver after partial hep-
atectomy (PH), in which S-adenosylmethionine levels dras-
tically decrease shortly after the intervention, coinciding
with the onset of DNA synthesis and the induction of early
response genes.14 When this decrease in S-adenosylmethi-
onine after PH was prevented by the addition of S-adeno-
sylmethionine, hepatocyte DNA synthesis was inhibited.33,34
Similarly, addition of S-adenosylmethionine inhibits the
mitogenic activity of hepatocyte growth factor (HGF) in
hepatocytes in culture30,35 and prevents the growth of rat
HCC31,32 and of hepatoma cell lines.16 In HuH7 cells
differing only in the type of MAT gene that is expressed,
MAT2A expression associates with more rapid cell growth
(about 1.5-fold increase) and lower S-adenosylmethionine
content (about 2-fold reduction), whereas the opposite is
observed for MAT1A.16 Moreover, disruption of MAT1A in
mice induces the expression of hepatic MAT2A and of a
variety of genes involved in cell proliferation, a reduction in
S-adenosylmethionine content, liver hyperplasia, and,
finally, HCC.1,3 In hepatocytes, S-adenosylmethionine in-
hibits HGF-dependent induction of cyclin D1 and D2
expression without affecting the activation of extracellular
signal-regulated protein kinase (ERK) by HGF,24 suggest-
ing that S-adenosylmethionine is a negative modulator of
cell cycle progression. Our findings indicate that the 
subunit provides a proliferative advantage in human hepa-
toma cell lines and that this effect could be mediated
through its interaction with MAT II 2 and the down-
regulation of S-adenosylmethionine levels. This is the first
identification of a candidate biologic function for this pro-
tein. Whether the  subunit regulates DNA synthesis
similarly in other tumor and nontumor cells is unknown.
Future work may establish the presumptive value as a
prognosis marker that we suggest for the  subunit in
HCC.
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